drugset / Trial / NCT03020992
A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to demonstrate the effect of Certolizumab Pegol (CZP) treatment on the reduction of Anterior Uveitis (AU) flares in subjects with active axial Spondyloarthritis (axSpA) and a documented history of AU.
Timeline
- Start
- 2016-12-21
- Primary completion
- 2019-12-04
- Completion
- 2020-01-23
Outcome
Met primary endpoint
paper There was a significant 82% reduction in AAU flare event rate during CZP versus pre-baseline PMID 33854572 ↗
registry analysis (other test); Certolizumab Pegol (FAS); p <0.001; Rate ratio 0.180 (95% CI 0.116 to 0.281); Poisson regression NCT03020992 ↗
Publications
- Results Haroon N, Baskurt Z, Chim T, Inman RD, Kumke T, Tham R, Kim M, van der Horst-Bruinsma I, Gensler LS. Certolizumab Pegol Reduced Anterior Uveitis Flares Compared With Standard Non-Biologic Treatment: Results From an Overlap Weighting Analysis in High-Risk Patients With Axial Spondyloarthritis. Int J Rheum Dis. 2026 Apr;29(4):e70621. doi: 10.1111/1756-185x.70621.
- van der Horst-Bruinsma IE, van Bentum RE, Verbraak FD, Deodhar A, Rath T, Hoepken B, Irvin-Sellers O, Thomas K, Bauer L, Rudwaleit M. Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study. Ther Adv Musculoskelet Dis. 2021 Mar 29;13:1759720X211003803. doi: 10.1177/1759720X211003803. eCollection 2021.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Certolizumab Pegol | Protein / enzyme biologic | 200 mg | Subcutaneous |